image credit- shutterstock
Insilico Medicine, a Hong Kong-based clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has announced a multi-target strategic alliance with Taiwan's Bora Pharmaceuticals, a global leader in pharmaceutical manufacturing.
The proposed alliance will be governed by definitive agreements to be discussed and executed by Insilico and Bora and is designed to combine Insilico's proprietary Pharma.AI platform, spanning target discovery, generative chemistry, and molecule optimization, with Bora's global development, manufacturing, quality, and commercialisation capabilities.
By linking AI-enabled discovery with automation-driven development, manufacturing, and quality execution, Insilico and Bora aim to pioneer a next-generation drug innovation model that connects novel molecule design with the capabilities required to develop, manufacture, and deliver medicines to patients with unmet medical needs.
The alliance lays the foundation for a broad, multi-target collaboration framework, subject to the parties' further discussion and execution of definitive agreements. If fully implemented, the potential value of the proposed collaboration could exceed $2.5 billion. Insilico expects to support Bora in strengthening AI capabilities across its global workforce and enhancing AI literacy across the organization.
The partnership is also expected to apply Insilico's AI capabilities to improve efficiency across manufacturing, supply chain, distribution, and corporate operations. As the collaboration progresses, Bora and Insilico expect to further refine its scope, scale, and operating framework.
As part of the alliance, Insilico aims to accelerate Bora's transition toward more AI-driven and automation-driven drug discovery and development capabilities by providing comprehensive research and development strategies and end-to-end AI solutions across global discovery and development workflows.
